MS Briefs

MS: Correlation between muscle strength and walking performance


 

Key clinical point: The correlation of muscle strength in the lower extremity and trunk with walking performance is stronger in patients with multiple sclerosis (MS) having mild disability than in those having moderate disability.

Major finding: The mild vs. moderate disability group exhibited stronger Pearson correlations of muscle strength to Timed 25-Foot Walk ( P less than .001) and 6-minute walk test ( P less than .001). For Timed 25-Foot Walk, ankle dorsiflexion ( P = .002), knee extension ( P = .001), and hip abduction ( P = .046) had significantly higher beta coefficients in the mild than moderate disability group.

Study details: A cross-sectional study analyzed data of patients with MS having mild disability (Expanded Disability Status scale [EDSS], 0-3.5; n=36) and moderate disability (EDSS, 4.0-5.5; n=36).

Disclosures: Dr J Kittelson received consulting fees for work on advisory and steering committees for CPC Clinical Research, Bayer Healthcare, Janssen Pharmaceuticals, and Pfizer and for work on data and safety monitoring committees from the Cystic Fibrosis Foundation Therapeutics, Novo Nordisk, Pfizer, Genentech, and BioMarin Pharmaceuticals. Dr MM Mañago, J Callesen, U Dalgas, and M Schenkman declared no conflicts of interest. The study did not receive any external funding.

Citation: Mañago MM et al. Mult Scler Relat Disord. 2020 Mar 13. doi: 10.1016/j.msard.2020.102052

Recommended Reading

Herpes zoster infection with MS treatment higher in women?
ICYMI Multiple Sclerosis
Is hematopoietic stem cell transplant linked to neurotoxicity in MS?
ICYMI Multiple Sclerosis
MS: Effects of vitamin D3 supplementation on inflammatory cytokines
ICYMI Multiple Sclerosis
Pro-inflammatory diet during adolescence is a risk factor for MS onset
ICYMI Multiple Sclerosis
Long-term effectiveness of induction vs escalation therapy in relapsing-remitting MS
ICYMI Multiple Sclerosis
Function in MS may vary significantly within EDSS scores
ICYMI Multiple Sclerosis
Cannabis misconceptions still common among MS clinicians
ICYMI Multiple Sclerosis
FDA approves Uplizna for treatment of anti-AQP4 antibody–positive NMOSD
ICYMI Multiple Sclerosis
Relapsing, progressive MS classifications should be abandoned
ICYMI Multiple Sclerosis
CMSC MRI guidelines evolve into international consensus protocol
ICYMI Multiple Sclerosis